Holen Sie sich die Stockscreener-App
0.00
100.00%
-7.87
Schlusskurs vom Vortag:
$7.87
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$594.49M
Einnahmen:
$83.57M
Nettoeinkommen (Verlust:
$-4.94M
KGV:
0.00
EPS:
-0.07
Netto-Cashflow:
$6.97M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$9.18
Chromadex Corp Stock (CDXC) Company Profile
Firmenname
Chromadex Corp
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie CDXC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDXC
Chromadex Corp
|
0.00 | 594.49M | 83.57M | -4.94M | 6.97M | -0.07 |
|
KHC
Kraft Heinz Co
|
25.68 | 31.47B | 25.43B | 2.66B | 3.03B | 2.19 |
|
JBS
Jbs N V
|
13.66 | 30.77B | 88.95B | 2.16B | 374.50M | 0.9748 |
|
GIS
General Mills Inc
|
52.96 | 29.84B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
78.94 | 28.25B | 12.63B | 1.38B | 863.00M | 3.96 |
|
MKC
Mccormick Co Inc
|
73.20 | 20.28B | 6.68B | 792.60M | 774.40M | 2.94 |
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Chromadex Corp Aktie (CDXC) Neueste Nachrichten
ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com - Defense World
ChromaDex (NASDAQ:CDXC) Now Covered by StockNews.com - Defense World
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - BioSpace
Supplement Maker Rebrands - Los Angeles Business Journal
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - MarketScreener
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments - MarketScreener
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - BioSpace
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com India
Niagen Bioscience maintains stability amid tariffs - Investing.com Australia
ChromaDex (NASDAQ:CDXC) Coverage Initiated at StockNews.com - Defense World
ChromaDex: Q4 Earnings Snapshot - marketscreener.com
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Australia
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
Why ChromaDex Corp (CDXC) Is Surging In 2025? - Insider Monkey
Botanical Supplements Market In-depth Insights, Business - openPR.com
Why These 15 Defensive Stocks Are Surging In 2025 - Insider Monkey
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - Marketscreener.com
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com India
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors By Investing.com - Investing.com UK
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire Inc.
ChromaDex Corporation will Change its Ticker to NAGE from CDXC - MarketScreener
ChromaDex Corporation will Change its Name to Niagen Bioscience, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
ChromaDex’s (CDXC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com
ChromaDex to rebrand as Niagen Bioscience and change ticker By Investing.com - Investing.com Australia
Q1 Earnings Forecast for ChromaDex Issued By HC Wainwright - Defense World
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - BioSpace
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com India
Major Rebrand: ChromaDex Evolves to Niagen Bioscience, Sharpens Focus on Aging Science - StockTitan
ChromaDex to Present at the 37th Annual Roth Conference - BioSpace
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - StockTitan
ChromaDex (NASDAQ:CDXC) Given New $11.00 Price Target at HC Wainwright - Defense World
ChromaDex stock price target raised to $11 by H.C. Wainwright - Investing.com Australia
Chromadex corp. SVP buys $2,145 worth of common stock - Investing.com
Finanzdaten der Chromadex Corp-Aktie (CDXC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Chromadex Corp-Aktie (CDXC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
0.09%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):